Clinical momentum Inhibrx has a clinical stage focus with a lead candidate showing positive Phase-2 results for ozekibart in a rare bone cancer, signaling near-term commercial potential and opportunities for partnerships or co-development with cancer research networks and specialty clinics.

Radiopharmaceuticals Strategic collaborations with NorthStar Medical Radioisotopes to develop and produce novel radiopharmaceuticals for cancer treatment suggest a sales path for radiopharmacy services, manufacturing capacity, and related regulatory/commercial support.

sdAb platform A modular single domain antibody platform enabling multivalent and multispecific formats offers opportunities to co-develop or license technology with pharma/biotech firms seeking targeted, tumor-restricted therapies and bespoke target engagement.

Biotech partnerships Repeated partnerships and biomarker collaboration (Genialis on predictive biomarkers for INBRX-109 and solid tumors) indicate a market for precision medicine data services, companion diagnostics, and analytics collaborations to de-risk clinical programs.

Financial resilience With substantial funding and a robust cash position (funding near half a billion) coupled with a diversified pipeline, there is room for milestone-driven partnerships, upfront licensing deals, and multi-program collaboration arrangements to scale business development efforts.